XOMA Royalty Corporation (LON:0M26)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 390.45M +72.6% |
| Revenue (ttm) | 36.77M +13.2% |
| Net Income | 15.09M |
| EPS | 1.19 |
| Shares Out | n/a |
| PE Ratio | 25.87 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59 |
| Open | 42.23 |
| Previous Close | 42.25 |
| Day's Range | 41.92 - 42.24 |
| 52-Week Range | 22.57 - 42.85 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About XOMA Royalty
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets ... [Read more]
News
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following cash di...
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on June 12, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on June 10, 2026, providing details for shareholder voting and corporate governance matters.
Xoma downgraded to Hold from Buy at Benchmark
Benchmark analyst Robert Wasserman downgraded Xoma (XOMA) to Hold from Buy after Ligand Pharmaceuticals (LGND) announced a definitive agreement to acquire Xoma for $39 per share in cash. Published fir...
XOMA Royalty Transcript: AGM 2026
The meeting covered director elections, auditor ratification, incentive plan amendments, and executive compensation. All proposals passed with a quorum present, and no shareholder questions were raised during the session.
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Quarterly report: Q1 2026
XOMA Royalty has published its Q1 2026 quarterly earnings report on May 12, 2026.
XOMA Royalty Slides: Q1 2026
XOMA Royalty has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Xoma downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis downgraded Xoma (XOMA) to Neutral from Buy with a $39 price target citing the pending acquisition by Ligand.
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo...
Ligand price target raised to $255 from $230 at Stifel
Stifel raised the firm’s price target on Ligand (LGND) to $255 from $230 and keeps a Buy rating on the shares after the company agreed to acquire Xoma (XOMA) for…
Xoma downgraded to Neutral from Buy at Lucid Capital
Lucid Capital analyst Elemer Piros downgraded Xoma (XOMA) to Neutral from Buy with a price target of $39, down from $66, after Ligand Pharmaceuticals (LGND) announced a definitive agreement to…
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Ligand to acquire Xoma for $39.00 per share in cash
Ligand (LGND) and Xoma (XOMA) announced that the companies have entered into a definitive agreement under which Ligand will acquire Xoma Royalty for $39.00 per share of common stock in…
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por...
Ligand to buy Xoma for $39 per share, WSJ reports
Ligand Pharmaceuticals (LGND) has reached a roughly $740M deal to buy Xoma XOMA Royalty (XOMA) at $39 per share, people familiar with the matter told The Wall Street Journal. The…
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on March 30, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on March 30, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Roy...
XOMA Royalty Earnings Call Transcript: Q4 2025
2025 saw strong financial growth, with royalty receipts up 68% year-over-year and positive operating cash flow enabling $16 million in share buybacks. The portfolio expanded to over 120 assets, with several late-stage catalysts expected in 2026 and a focus on disciplined capital allocation.
XOMA Royalty Annual report: Q4 2025
XOMA Royalty has published its Q4 2025 annual report on March 18, 2026.
XOMA Royalty Earnings release: Q4 2025
XOMA Royalty released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
XOMA Royalty Slides: Q4 2025
XOMA Royalty has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 18, 2026.
Xoma reports Q4 EPS 26c, consensus (13c)
Reports Q4 revenue $13.8M, consensus $11.05M. “We continue to search for innovative ways to drive enhanced optionality in the XOMA (XOMA) portfolio, with the addition of 22 assets and two…